DeLong Mark Jeffrey Insider Trading Activity (APLS)

Profile

Mark Jeffrey Delong is listed as Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc. based on SEC filings (CIK 0001856078) with the most recent filing dated 2026-01-15. In this role, he is responsible for corporate strategy, business development, and partnerships to advance Apellis' portfolio in complement inhibition therapies.

Role	Insider
Notability	35/100

Board memberships

Apellis Pharmaceuticals, Inc.

Awards & honors

Led corporate strategy and development initiatives at Apellis
Oversaw business development activities to expand the product portfolio
Drove strategic partnerships and potential licensing discussions

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	21.4K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	8.5K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	4.9K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	36.6K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	18.3K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	18.3K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	36.6K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	36.6K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	19.0K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	19.0K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	D — Derivative transaction	41.2K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	41.2K	—
2026-05-14	APLS	Apellis Pharmaceuticals, Inc.	J — Other acquisition / disposition	114.6K	—
2026-02-13	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	368	$22.15	$8K
2026-01-30	APLS	Apellis Pharmaceuticals, Inc.	A — Grant or award	36.6K	$0.00
2026-01-23	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	3.4K	$21.77	$73K
2026-01-21	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	1.3K	$19.79	$26K
2026-01-15	APLS	Apellis Pharmaceuticals, Inc.	S — Open-market sale	1.8K	$22.19	$39K

Frequently Asked Questions

Who is DeLong Mark Jeffrey?

How many SEC Form 4 filings has DeLong Mark Jeffrey submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has DeLong Mark Jeffrey been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 4 open-market sales ($147K) across all tracked filings.

Where can I see all of DeLong Mark Jeffrey's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

DeLong Mark Jeffrey — SEC Form 4 Insider Trading Activity

Summary